ARS Pharmaceuticals (SPRY) reported a Q2 net loss late Thursday of $0.63 per diluted share, widening from a loss of $0.46 a year earlier.

Four analysts polled by FactSet expected a loss of $0.48.

Revenue for the quarter ended June 30 was $33.7 million, up from $15.7 million a year earlier.

Four analysts expected $31.3 million.

The company said it had $143.8 million in cash, cash equivalents, and short-term investments as of June 30, and expects to reach cash flow breakeven by the end of 2027.